ALT

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Gaithersburg, Maryland. Originally known as Vaxin Inc., the company changed its name to Altimmune in September 2015. The company went public in May 2017 and focuses on developing innovative treatments for metabolic diseases, particularly obesity and liver conditions. Altimmune has evolved from its early vaccine development roots to become a specialized developer of dual-mechanism therapies targeting the growing global obesity and non-alcoholic fatty liver disease epidemics.